FDA Expands Vyvgart Label to All Adult Patients with Generalized Myasthenia Gravis

The FDA has expanded approval for efgartigimod alfa-fcab (brand name Vyvgart)and efgartigimod alfa and hyaluronidase-qvfc (brand name VyvgartHytrulo), significantly broadening treatment access for adults living with generalized myasthenia gravis (gMG), according to an announcement from argenx.¹ The updated indication now includes all adult gMG patients regardless of antibody subtype, including anti-acetylcholine receptor (AChR) antibody-positive, anti-muscle-specific kinase antibody-positive, anti-LRP4 antibody-positive, and triple seronegative patients.¹

The decision marks an important expansion for the FcRn-blocking therapy franchise and addresses a longstanding unmet need among seronegative gMG patients, who historically have had fewer targeted treatment options available.²

Broadening Access for Seronegative Patients

Generalized myasthenia gravis is a chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue. While many approved therapies have focused on patients with detectable AChR antibodies, a subset of patients do not test positive for those antibodies, complicating diagnosis and treatment selection.³

According to argenx, the FDA approval was supported by findings from the Phase 3 ADAPT SERON study, which demonstrated rapid and sustained symptom improvement among seronegative gMG patients treated with Vyvgart.¹ The company stated that efficacy outcomes continued with ongoing treatment cycles, reinforcing the role of pathogenic immunoglobulin G (IgG) antibodies across multiple gMG subtypes.¹

“Today’s approval means that all adult gMG patients, regardless of serotype, can now benefit from Vyvgart’s rapid onset, sustained disease control, and favorable safety profile,” said Luc Truyen, MD, PhD, chief medical officer at argenx, in the company announcement.¹

The expanded label also positions Vyvgart and Vyvgart Hytrulo as the first approved therapies for all serotypes of adult gMG patients.²

Growing Momentum for FcRn Inhibition

The FDA’s action further strengthens the commercial and clinical momentum behind FcRn inhibition, an emerging therapeutic approach designed to reduce circulating pathogenic IgG antibodies. Vyvgart was the first approved FcRn blocker for gMG and has continued to expand into additional autoimmune indications.¹

Industry analysts have noted strong uptake of the therapy across both gMG and chronic inflammatory demyelinating polyneuropathy (CIDP), another approved indication for the product line.⁴ In a recent business update, argenx reported continued physician adoption and increased use of Vyvgart earlier in treatment pathways.⁴

The company is also advancing additional studies involving ocular myasthenia gravis, immune thrombocytopenia, Sjögren disease, and myositis, reflecting broader interest in FcRn-targeted therapies across autoimmune diseases.⁴

Implications for the Neurology Community

Patient advocacy organizations welcomed the expanded approval, emphasizing the significance for patients with seronegative disease who often face delayed diagnosis and limited treatment access.²

The Muscular Dystrophy Association stated that the approval represents “meaningful progress” for individuals living with seronegative generalized myasthenia gravis.² The organization also highlighted the importance of increasing treatment options to help reduce disease burden and improve quality of life.²

For clinicians, the broadened label may simplify prescribing decisions by enabling treatment access independent of antibody subtype testing.¹ As diagnostic approaches continue to evolve, broader indications may help streamline care for a more heterogeneous patient population.

The approval also reinforces the growing role of precision immunology in neurology, particularly as developers pursue therapies capable of addressing multiple autoimmune pathways with a single mechanism of action.

References

1. argenx announces U.S. FDA approval expanding VYVGART and VYVGART Hytrulo for use in all adult patients living with gMG. (2026, May 8). GlobeNewswire. https://www.globenewswire.com/news-release/2026/05/08/3291372/0/en/argenx-announces-u-s-fda-approval-expanding-vyvgart-and-vyvgart-hytrulo-for-use-in-all-adult-patients-living-with-gmg.html

2. FDA expands approval of VYVGART and VYVGART Hytrulo to all adults living with generalized myasthenia gravis. (2026, May 8). Muscular Dystrophy Association. https://www.mda.org/press-releases/fda-expands-approval-of-vyvgart-and-vyvgart-hytrulo-to-all-adults-living-with-generalized-myasthenia
3. Maia, M. (2026, January 14). FDA grants priority review for expanded Vyvgart use in gMG. Myasthenia Gravis News. https://myastheniagravisnews.com/news/fda-grants-priority-review-expanded-vyvgart-use-gmg/
4. argenx reports first quarter 2026 financial results and provides business update. (2026, May 7).Yahoo Finance. https://finance.yahoo.com/sectors/healthcare/articles/argenx-reports-first-quarter-2026-050000022.html